Inpharmatica adds ADME with Arqule

- Last updated on GMT

Related tags: Protein

UK informatics company Inpharmatica has added a whole new suite of
ADME (absorption, distribution, metabolism and excretion)
capabilities to its drug lead optimisation services with the
purchase of a lab and intellectual property from Arqule.

UK informatics company Inpharmatica has added a whole new suite of ADME (absorption, distribution, metabolism and excretion) capabilities to its drug lead optimisation services with the purchase of a lab and intellectual property from Arqule.

Inpharmatica says that the completion of the deal will enhance the reach of its proprietary PharmaCarta product, which enables the simultaneous exploration of bioinformatics, chemogenomics, disease indication and pharmacology. The company said that the acquisition would allow it to provide in silico and in vitro ADME screening services, as well as consultancy.

Under the terms of the deal, 15 of ArQule's UK staff will join Inpharmatica. Financial terms of the transaction were not disclosed.

Meanwhile, Inpharmatica has launched a new online version of its Biopendium database. This product, which is updated quarterly, details more than 6 billion protein relationships derived from around 2.6 million sequences, including ligand and structure information. It is used by researchers trying to assign function to protein sequences.

For additional information about licensing Biopendium Online, contact Richard Lingard​, Inpharmatica's director of business development.

Related topics: Preclinical Research

Related news

Follow us

Products

View more

Webinars